TRISALUS LF SC CM A (TLSI)
Health Care · Clinical-stage biopharma and medical devices · NASDAQ
TriSalus is a medical technology company integrating proprietary pressure-enabled drug delivery devices with immunotherapeutics to improve outcomes for patients with liver and pancreatic cancer.
What TRISALUS LF SC CM A does
TriSalus Life Sciences is a commercial-stage medical device and Phase I clinical-stage pharmaceutical company. The company commercializes TriNav, a medical device product, and is developing nelitolimod, a pharmaceutical product candidate, along with other product candidates utilizing Pressure-Enabled Drug Delivery (PEDD) technology. The company operates with significant net losses and accumulated deficit, relying on capital raising and strategic partnerships to fund continued development and commercialization efforts.
Themes: interventional oncology, drug delivery systems, immunotherapy, liver cancer treatment, pancreatic cancer treatment
Fundamentals
- Price$5.27 as of 2026-08-21 close
- Market cap$324M as of 2026-08-21
- 1-year return+6.3% 2025-08-21 close $4.96 → 2026-08-21 close $5.27
- P/En/a negative earnings
- Net margin-60.9% as of 2026-08-24
- Gross margin+85.1% as of 2026-08-24
- ROE+12.0% as of 2026-08-24
- Debt / equity2.58 as of 2026-08-24
- Revenue growth (YoY)+39.6% as of 2026-08-24
- Revenue CAGR (3y)+53.9% SEC XBRL
- Beta0.43 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How TLSI compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross margintop 25% 384 covered Health Care peers, as of 2026-08-24
- return on equitytop 25% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRtop 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How TRISALUS LF SC CM A looks technically
TRISALUS LF SC CM A (TLSI) is trading 9.0% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed below its 200-day average about 106 trading days ago — a "death cross", a bearish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 31, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 58, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 2 trading days ago (its momentum flipped negative). It made a new 20-day high about 9 trading days ago. It is 33.7% below its highest point of the past year. Trading volume is unusually light — only about 48% of its 30-day average.
Trend
9
| Distance from the 200-day | it is trading 9.0% above its 200-day average, the long-term trend line — a longer-term uptrend | +9.0% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $4.55 | $4.55 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $4.83 | $4.83 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 8 calendar days ago — the swings before that are what the structure reading is measured on | 8 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that upward direction; the labelling fails if price closes below 4.41. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a completed three-part correction. | possible upward five-wave sequence, in wave 4 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 106 trading days ago — a "death cross", a bearish long-term signal | 106 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 9.0% above | +9.0% |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 31, with buyers in control | 31.1 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 58, neither overbought (above 70) nor oversold (below 30) | 58.0 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($4.44 to $5.91) — its "stochastic" reading is 56 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 56.5 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 2 trading days ago (its momentum flipped negative) | 2 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $7.95 | $7.95 |
|---|---|---|
| From the 52-week high | it is 33.7% below its 52-week high (its highest price of the past year) | -33.7% |
| Above the 52-week low | it is 139.5% above its 52-week low (its lowest price of the past year) | +139.6% |
| Below the 52-week high | it is 33.7% below its highest point of the past year | 33.7% |
| Since a 20-day breakout | it made a new 20-day high about 9 trading days ago | 9 sessions |
| Since a 55-day breakout | it made a new 55-day high about 9 trading days ago | 9 sessions |
| All-time high | its highest closing price on record is $16.24 (set on 2023-08-11) | $16.24 |
| Given back of the 52-week move | over the past year its closes ranged ($2.52 to $7.50), and it has recovered around half of its fall from last year’s high — 55% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $5.60 to $5.76. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 55.2% |
| From the all-time high | it is 67.5% below its all-time high | -67.5% |
| Nearest price level | it is trading 1.1% below a resistance level at $5.33 — a price it turned at three times since 2025-01-10, most recently on 2025-10-21. Since 2024-08-21 it has 10 such levels below the current price and 3 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +1.1% |
| All-time low | its lowest closing price on record is $2.20 (set on 2026-05-13) | $2.20 |
| Above the all-time low | it is 139.5% above its all-time low | +139.6% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 60th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.3227 between its high and its low — about 6.1% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.3227 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $4.09 and $6.04 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $4.09 – $5.07 – $6.04 |
| Typical daily range (% of price) | its price moves about 6.1% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.1% |
| Stretch from the 200-day average | it is trading 1.4 daily ranges above its 200-day average price (9.0% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.4 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 48% of its 30-day average | 0.48× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 11.1% since the prior reading | +11.1% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a doji | 2 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 2 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.4% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.4% |
|---|---|---|
| Open gap | it gapped 12.5% above the previous close 49 sessions ago and has not traded back through the level it left behind at 3.21 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +12.5% |
| Gap filled | a 2.1% gap down opened on 2026-08-10 has been "filled" 9 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 9 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 19.1 percentage points (the stock gained 21.4% while the market gained 2.3%) | +19.1% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 49.7 percentage points (the stock gained 52.8% while the market gained 3.1%) | +49.7% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 14.4 percentage points (the stock lost 3.3% while the market gained 11.1%) | -14.4% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 14.2 percentage points (the stock gained 6.3% while the market gained 20.5%) | -14.2% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, trading above its 200-day average, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, MACD momentum is negative, lagging the market over 6 months — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 29% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thick, spanning 10.3% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | +29.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 31% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $4.02 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | +31.0% |
|---|---|---|
| Vs the average paid since it last reported | the price is 4% below the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is under water. That average is $5.50 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | -4.1% |
Price levels it has turned at before
TLSI last closed at $5.27 on 2026-08-21. Since 2024-08-21 it has turned at 10 prices below its last close and 3 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $5.33 | Resistance | 1.1% above the last close | turned there three times · 2025-01-10 to 2025-10-21 |
| $5.11 | Support | 3.1% below the last close | turned there twice · 2025-02-25 to 2025-06-13 |
| $4.92 | Support | 6.6% below the last close | turned there four times · 2025-04-10 to 2026-06-26 |
| $5.67 | Resistance | 7.5% above the last close | turned there five times · 2025-01-27 to 2026-02-26 |
| $4.80 | Support | 8.9% below the last close | turned there 8 times · 2024-09-04 to 2026-05-12 |
| $5.86 | Resistance | 11.2% above the last close | turned there four times · 2025-03-05 to 2026-08-13 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes below $4.41.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $4.96 and $5.46 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a completed three-part correction, which fails on a close above $5.91.
This reading has stood for 2 trading days, since 2026-08-20.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Tested and reclaimed 200-day support · Pulled back from the 12-month high · MACD just crossed bearish (12/26/9) · in a strong, established uptrend (ADX) · Analyst price target recently RAISED | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.25 mean, 1=Strong Buy…5=Strong Sell) — 4 analysts
- Mean price target$10.00 range $7.00 – $14.00; median $9.50
Analyst estimates, as of 2026-08-17. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Key risks (from latest filing)
["Limited operating history with accumulated deficit of $330.6 million as of December 31, 2025; significant ongoing losses with net losses of $39.2 million in 2025 and $30.0 million in 2024; uncertain path to profitability.","Dependence on raising additional capital through equity and debt financing; ability to access OrbiMed Credit Agreement and other funding sources is uncertain and may not be available on favorable terms.","Clinical development and regulatory approval risks for nelitolimod and other product candidates; preclinical testing and clinical trials are time-consuming, expensive, and uncertain with no guarantee of regulatory approval or commercial success."]
What changed in the latest 10-Q
AI-assisted comparison of TLSI's 10-Q filed 2026-05-12 against the prior one filed 2025-11-13.
Management's Discussion & Analysis (MD&A)
- Added:
- Added full company name 'TriSalus Life Sciences, Inc.' with parenthetical clarification of pronouns used in section
- Added reference to 'TriSalus' as alternative name for the Company
- Added reference to audited financial statements 'as of and for the year ended December 31, 2025'
- Added SEC filing date 'March 5, 2026' for the Annual Report on Form 10-K
- Removed:
- Removed reference to year ended December 31, 2024
- Removed SEC filing date 'April 15, 2025' for prior year Annual Report
- Removed phrase 'For a complete discussion of forward-looking statements, see the section above entitled'
- Removed quotation mark closure around 'Cautionary Note Regarding Forward Looking Statements'
- Reworded:
- Changed 'should be read in conjunction with' to 'should be read together with'
- Changed 'TriSalus' condensed consolidated financial statements' to 'TriSalus' condensed consolidated financial statements' (added possessive clarification with company name)
- Changed 'Information included in this Form 10-Q, including information with respect to our plans and strategy for our business, includes forward-looking statements' to 'Some of the information contained in this discussion and analysis includes forward-looking statements'
- Changed reference from 'section above entitled' to 'section titled'
- Notes:
- Both document excerpts are truncated at the same point ('section captioned "'), limiting full comparison of subsequent content
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days.
- Last 180 days6 buys ($2M) · 1 sell ($1450) — 5 buying, 1 selling insiders
Cluster buying: 5 different insiders reported open-market purchases (SEC code P) of TLSI within a 30-day window between 2026-05-15 and 2026-05-15. Disclosed Form 4 activity, not a prediction of performance or a buy signal.
Most recent open-market transaction: 2026-05-15. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about TLSI's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding TLSI as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 1,859,783
- Reported value $7,439,132
reported quarterly holdings change (2025-12-31 → 2026-03-31): 1 new, 1 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
TLSI had 3,773,177 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
TLSI had 6.13% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 22.15 days to cover at the same settlement.
- Reported short interest (shares) 3,773,177
- Short interest (% of shares outstanding) 6.13%
- Prior settlement (shares) 3,564,595
- Reported change 5.85%
- Days to cover (reported) 22.15
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Boston Scientific (BSX)
- Medtronic (MDT)
- Cook Medical
- Terumo (TRUMY)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare TLSI vs…
TRISALUS LF SC CM A is found in…
Frequently asked questions
What does TRISALUS LF SC CM A (TLSI) do?
TriSalus Life Sciences is a commercial-stage medical device and Phase I clinical-stage pharmaceutical company. The company commercializes TriNav, a medical device product, and is developing nelitolimod, a pharmaceutical product candidate, along with other product candidates utilizing Pressure-Enabled Drug Delivery (PEDD) technology.
What sector is TRISALUS LF SC CM A (TLSI) in?
TRISALUS LF SC CM A (TLSI) is classified in the Health Care sector. Its industry is Clinical-stage biopharma and medical devices. It trades on NASDAQ.
Who are TRISALUS LF SC CM A's (TLSI) competitors?
Notable peers of TRISALUS LF SC CM A (TLSI) include Boston Scientific, Medtronic, Cook Medical and Terumo. This peer set is informational only — not financial advice.
Is TRISALUS LF SC CM A (TLSI) overbought or oversold right now?
TRISALUS LF SC CM A (TLSI) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 58, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on TLSI come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.